Olszewski, A., Matasar, M., Huntington, S., Bonal, D., Ollila, T., Pelcovits, A., Tiger, Y. K., Reagan, J., Chorzalska, A., Morgan, J., Pardo, M., McMahon, J., Donnelly, S., Carmody, C., Margolis, J., Milrod, C., Dubielecka, P. (2025). Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial. Blood. https://doi.org/10.1182/blood-2025-1003